Stock Scorecard



Stock Summary for Legend Biotech Corp (LEGN) - $21.70 as of 9/3/2026 8:31:11 AM EST

Total Score

10 out of 30

Safety Score

33 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LEGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LEGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LEGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LEGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LEGN (33 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for LEGN

(LEGN) as a Liquidity Pulse for Institutional Tactics 9/1/2026 3:10:00 PM
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference 9/1/2026 12:39:00 PM
Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative? 8/25/2026 8:44:00 PM
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Report - Results, Call & Slides 8/22/2026 4:14:00 PM
Legend Biotech (LEGN) RSU grant lifts interim CEO stake to 35,142 shares 8/18/2026 8:40:00 PM
Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards 8/18/2026 8:01:00 PM
How Legend Biotech’s Q2 Profitability Jump and Interim CEO Shift Will Impact Legend Biotech (LEGN) Investors 8/18/2026 8:42:00 AM
Legend Biotech Corporation (LEGN): Investor Outlook on a Biotech Powerhouse with 141.76% Potential Upside 8/17/2026 10:40:00 AM
Certain Ordinary Shares of Legend Biotech Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2026. 8/16/2026 4:10:00 AM
Certain Options of Legend Biotech Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2026. 8/16/2026 12:13:00 AM

Financial Details for LEGN

Company Overview

Ticker LEGN
Company Name Legend Biotech Corp
Country N/A
Description Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 21.70
Price 4 Years Ago 49.92
Last Day Price Updated 9/3/2026 8:31:11 AM EST
Last Day Volume 1,306,607
Average Daily Volume 2,471,687
52-Week High 37.50
52-Week Low 16.24
Last Price to 52 Week Low 33.62%

Valuation Measures

Trailing PE N/A
Industry PE 40.38
Sector PE 44.74
5-Year Average PE -113.78
Free Cash Flow Ratio 6.27
Industry Free Cash Flow Ratio 37.58
Sector Free Cash Flow Ratio 35.74
Current Ratio Most Recent Quarter 3.04
Total Cash Per Share 3.46
Book Value Per Share Most Recent Quarter 6.35
Price to Book Ratio 3.29
Industry Price to Book Ratio 4.31
Sector Price to Book Ratio 8.85
Price to Sales Ratio Twelve Trailing Months 3.23
Industry Price to Sales Ratio Twelve Trailing Months 50.70
Sector Price to Sales Ratio Twelve Trailing Months 40.40
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 194,488,000
Market Capitalization 4,220,389,600
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -67.66%
Reported EPS 12 Trailing Months -0.51
Reported EPS Past Year -0.06
Reported EPS Prior Year -1.60
Net Income Twelve Trailing Months -91,604,000
Net Income Past Year -296,800,000
Net Income Prior Year -177,026,000
Quarterly Revenue Growth YOY 51.90%
5-Year Revenue Growth 68.83%
Operating Margin Twelve Trailing Months 14.90%

Balance Sheet

Total Cash Most Recent Quarter 672,921,702
Total Cash Past Year 901,900,000
Total Cash Prior Year 286,749,000
Net Cash Position Most Recent Quarter 500,991,702
Net Cash Position Past Year 600,704,000
Long Term Debt Past Year 301,196,000
Long Term Debt Prior Year 301,196,000
Total Debt Most Recent Quarter 171,930,000
Equity to Debt Ratio Past Year 0.77
Equity to Debt Ratio Most Recent Quarter 0.88
Total Stockholder Equity Past Year 1,002,100,000
Total Stockholder Equity Prior Year 1,040,546,000
Total Stockholder Equity Most Recent Quarter 1,229,639,657

Free Cash Flow

Free Cash Flow Twelve Trailing Months -255,614,012
Free Cash Flow Per Share Twelve Trailing Months -1.31
Free Cash Flow Past Year -168,043,258
Free Cash Flow Prior Year -158,138,000

Options

Put/Call Ratio 3.67
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.53
MACD Signal -0.82
20-Day Bollinger Lower Band 16.45
20-Day Bollinger Middle Band 25.47
20-Day Bollinger Upper Band 34.49
Beta 0.39
RSI 43.64
50-Day SMA 24.96
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 9/4/2026 2:45:06 AM EST